10-Q: ZimVie Inc. Reports Third Quarter 2024 Results Following Spine Segment Divestiture

ZimVie Inc. reports a net loss of $2.284 million for the third quarter of 2024, following the sale of its spine segment.

Summary

• ZimVie Inc. reported a net loss of $2.284 million for the three months ended September 30, 2024, compared to a net loss of $5.089 million for the same period in 2023.
• Net sales for the quarter were $103.222 million, a decrease from $105.311 million in the prior year.
• The company completed the sale of its spine segment on April 1, 2024, for a total purchase price of $377.2 million, receiving $311.8 million in proceeds, excluding a $60 million promissory note and transaction costs.
• The company recognized a gain of $11.3 million on the sale of the spine segment, which is included in discontinued operations.
• Operating expenses for the quarter were $108.059 million, compared to $109.194 million in the same period last year.
• The company's restructuring initiatives resulted in pre-tax charges of $0.7 million for the quarter and $3.5 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents were $68.096 million as of September 30, 2024, compared to $75.449 million at the end of September 2023.
• The company prepaid $275 million on its term loan using proceeds from the spine segment sale, and made an additional optional prepayment of $15 million.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the decrease in sales and the reported net loss, despite the successful divestiture of the spine segment and debt reduction. The company is still in a transitional phase and faces challenges in the dental market.

Positives

• The net loss improved compared to the same quarter last year, decreasing from $5.089 million to $2.284 million.
• The company successfully completed the sale of its spine segment, generating $311.8 million in cash proceeds and a $60 million promissory note.
• The company reduced its debt by prepaying $275 million on its term loan using proceeds from the spine segment sale.
• Intangible asset amortization decreased due to certain assets becoming fully amortized in 2023.
• The company's restructuring initiatives are aimed at streamlining operations and reducing costs.

Negatives

• Net sales decreased by 2.0% year-over-year, reaching $103.222 million.
• The company experienced a price decline in the three and nine months ended September 30, 2024, primarily related to pricing pressures on premium dental implant system sales in North America and declines in pricing in China.
• Research and development expenses increased in dollars and as a percentage of net sales.
• The company reported a net loss of $2.284 million for the quarter.
• The company's cash and cash equivalents decreased from $87.8 million at the end of 2023 to $68.1 million as of September 30, 2024.

Risks

• The company is exposed to risks from changes in foreign currency exchange rates, particularly with the Euro and Japanese Yen.
• The company faces pricing pressures on premium dental implant systems in North America and in China.
• The company is dependent on new product development, technological advances and innovation.
• The company is subject to various claims, legal proceedings and investigations.
• The company's ability to collect accounts receivable in some countries depends in part upon the financial stability of the hospital and healthcare sectors and the respective countries national economic and healthcare systems.
• The company is exposed to credit risk related to trade accounts receivable.

Future Outlook

The company believes that available cash and cash equivalents, cash flows generated through operations and cash available under its revolving credit facility will be sufficient to meet its liquidity needs, including capital expenditures, for at least the next 12 months.

Industry Context

The company operates in the medical technology industry, specifically in the dental implant, biomaterials and digital dentistry market. The sale of the spine segment allows the company to focus on its dental business. The company faces competition and pricing pressures in the dental implant market.

Comparison to Industry Standards

• The company's revenue decline of 2.0% year-over-year is below the average growth rate for the medical device industry, which has seen modest growth in recent quarters.
• The company's operating loss of $4.837 million is not unusual for a company undergoing restructuring and divestiture, but it is worse than some of its larger competitors in the dental implant market, such as Straumann and Danaher, which have reported positive operating income.
• The company's gross margin of approximately 65% is in line with industry standards for medical device companies, but it is lower than some of the more profitable dental implant companies.
• The company's R&D spending as a percentage of sales is slightly higher than the industry average, indicating a focus on innovation, but it is not yet translating into revenue growth.
• The company's debt levels are high, but the recent debt reduction from the sale of the spine segment is a positive step towards improving its financial position.

Legal Proceedings

• The company is subject to various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial and other matters that arise in the normal course of business.

Stakeholder Impact

• Shareholders may be concerned about the decrease in sales and the reported net loss.
• Employees may be affected by the ongoing restructuring initiatives.
• Customers may be impacted by changes in product offerings and pricing.
• Suppliers may be affected by changes in the company's supply chain.
• Creditors may be impacted by the company's debt levels and financial performance.

Next Steps

• The company will continue to focus on its dental business following the sale of the spine segment.
• The company will continue to implement restructuring initiatives to reduce costs and streamline operations.
• The company will continue to develop and launch new dental products.
• The company will monitor and manage its foreign currency exposure.
• The company will continue to monitor and manage its credit risk.

Key Dates

Keywords

dental implants, spine segment, restructuring, net sales, net loss, promissory note, term loan, discontinued operations, operating expenses, biomaterials, digital dentistry